Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Neurologix, Inc., a development stage company, engages in the discovery and development of therapeutic treatments for disorders of the brain and central nervous system. The company's treatments are designed as alternatives to conventional surgical and pharmacological treatments. It primarily focuses on gene therapy for treating Parkinson's disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the development of gene transfers for the treatment of neurodegenerative and metabolic disorders, including Huntington's disease, depression, and metabolic syndrome or genetically-based obesity. Neurologix, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.

Takara Bio Inc., develops, manufactures, and distributes a wide range of life science reagents and kits under the Takara®, Clontech®, and Cellartis® brands. Key products include SMART® cDNA synthesis kits for a variety of samples and applications, including NGS; high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium®, and Advantage® enzymes); Cellartis stem cells and stem cell reagents; RT enzymes and SMART library construction kits; the innovative In-Fusion® cloning system; Guide-it™ gene editing tools; Tet-based inducible gene expression systems; and Living Colors® fluorescent proteins. These and other products support applications including NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi, gene editing, and stem cell studies; and plant and food research

Avigen, Inc., a biopharmaceutical company, engages in identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials. The company was founded in 1992 and is headquartered in Alameda, California. As of December 18, 2009, Avigen, Inc. operates as a subsidiary of MediciNova Inc

The Research Institute at Nationwide Children's Hospital is one of America's ten largest free-standing pediatric research centers and works to enhance the health of children by engaging in research.

Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain.

The Schepens Eye Research Institute, Inc. operates as an eye research institute. It offers treatment for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. The company was founded by Charles L. Schepens in 1950 and is headquartered in Boston, MA.

Jichi Medical University (自治医科大学 Jichi ika daigaku) is a private university in Shimotsuke, Tochigi, Japan, established in 1972. In 2008 the Gates Foundation awarded $100,000 to Hiroyuki Matsuoka, a medical researcher at the university, to do research on flying syringes.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Part of uniQure NV, uniQure IP BV is a Dutch company that provides research and development services of human gene based therapies.

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Guangdong Topkang Biotechnology Co., Ltd., established on 2014-07-23, Business scope includes new material technology research and development;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Natural science research and experimental development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;Research and development of bio-based material polymerization technology;Biochemical product technology research and development;Extraction of marine bioactive substances,purification,Synthesis technology research and development;Biomass liquid fuel production process research and development;Biomass Energy Technology Services;3Dprint service;Technology intermediary service;Science popularization service;Development of Human Gene Diagnosis and Therapy Technology;New material technology promotion service;Internet of things technology research and development;Sales of Class I Medical Devices;Chemical product sales(No licensed chemical products);sales agent;Disinfectant sales(Free of Hazardous Chemicals);Sales of hygiene products and single-use medical products;Sales of Class II Medical Devices;Sales of formula food for special medical purposes;daily mask(non-medical)Sales;internet sales(Except for products that require a license for sale);Wearable smart device sales;Optical Instrument Sales;Optical Glass Sales;Experimental analysis instrument sales;Sales of bio-based materials;Sales of daily chemical products;Standardized service;

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Shenzhen ISKCONNING Biomedical Development Co., Ltd., established on 2019-08-07, Business scope includes general business items:New products in the field of biotechnology,new drug,new reagent,New Technology,Research and development of new technologies;Laboratory Biological Reagents,Sales of consumables;Basic technology research of biomedical technology;Bioengineering Technology Project Investment,technology transfer,technical consulting;Investing in the medical industry;Provide management consulting for medical institutions;Domestic Trade;Operating import and export business(above laws,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Vector Neurosciences, Inc. provides treatment for Parkinson disease. The company was founded by Michael Kaplitt and is headquartered in Wilmington, DE.